Anaphore said it acquired RuiYi for an undisclosed amount to gain access to its biologics drug discovery platform targeting G protein coupled receptors (GPCRs).
Anaphore, a US-based healthcare provider, has acquired a Chinese peer and closed on the $15m second tranche of its series A round.
Anaphore said it acquired RuiYi for an undisclosed amount to gain access to its biologics drug discovery platform targeting G protein coupled receptors (GPCRs).
The acquisition follows the hire in June of Paul Grayson as executive president.
At the time of the hire, Russell Greig, Anaphore’s executive chairman since leaving drugs company GlaxoSmithKline’s corporate venturing unit…
